{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:16:40Z","timestamp":1792790200372,"version":"4.5.0"},"reference-count":47,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2020,3,18]],"date-time":"2020-03-18T00:00:00Z","timestamp":1584489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81172892"],"award-info":[{"award-number":["81172892"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31370932"],"award-info":[{"award-number":["31370932"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the key project of innovative drug development","award":["2015ZX09101033"],"award-info":[{"award-number":["2015ZX09101033"]}]},{"name":"the key project of innovative drug development","award":["2016ZX09J16102-002"],"award-info":[{"award-number":["2016ZX09J16102-002"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Staphylococcus aureus (S. aureus) is a leading cause of both healthcare-and community-associated infections globally, which result in severe disease and readily developing antibiotic resistance. Developing an efficacious vaccine against S. aureus is urgently required. In the present study, we selected five conserved antigens, including the secreted factors \u03b1-hemolysin (Hla), staphylococcal enterotoxin B (SEB) and the three surface proteins staphylococcal protein A (SpA), iron surface determinant B N2 domain (IsdB-N2) and manganese transport protein C (MntC). They were all well-characterized virulence factor of S. aureus and developed a recombinant five-antigen S. aureus vaccine (rFSAV), rFSAV provided consistent protection in S. aureus lethal sepsis and pneumonia mouse models, and it showed broad immune protection when challenged with a panel of epidemiologically relevant S. aureus strains. Meanwhile, rFSAV immunized mice were able to induce comprehensive cellular and humoral immune responses to reduce bacterial loads, inflammatory cytokine expression, inflammatory cell infiltration and decrease pathology after challenge with a sub-lethal dose of S. aureus. Moreover, the importance of specific antibodies in protection was demonstrated by antibody function tests in vitro and in vivo. Altogether, our data demonstrate that rFSAV is a potentially promising vaccine candidate for defensing against S. aureus infection.<\/jats:p>","DOI":"10.3390\/vaccines8010134","type":"journal-article","created":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T03:54:14Z","timestamp":1584590054000},"page":"134","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Rapid and Broad Immune Efficacy of a Recombinant Five-Antigen Vaccine against Staphylococcus aureus Infection in Animal Models"],"prefix":"10.3390","volume":"8","author":[{"given":"Hao","family":"Zeng","sequence":"first","affiliation":[{"name":"National Engineering Research Center of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy, Third Military Medical University, Chongqing 400038, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6579-9787","authenticated-orcid":false,"given":"Feng","family":"Yang","sequence":"additional","affiliation":[{"name":"National Engineering Research Center of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy, Third Military Medical University, Chongqing 400038, China"},{"name":"Chengdu Olymvax Biotechnology Co., Ltd., Chengdu 611731, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Feng","sequence":"additional","affiliation":[{"name":"Chongqing Collaborative Innovation Center for Functional Food, Chongqing University of Education, Chongqing 400065, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyong","family":"Zhang","sequence":"additional","affiliation":[{"name":"National Engineering Research Center of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy, Third Military Medical University, Chongqing 400038, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Gu","sequence":"additional","affiliation":[{"name":"National Engineering Research Center of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy, Third Military Medical University, Chongqing 400038, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiming","family":"Jing","sequence":"additional","affiliation":[{"name":"National Engineering Research Center of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy, Third Military Medical University, Chongqing 400038, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changzhi","family":"Cai","sequence":"additional","affiliation":[{"name":"Chengdu Olymvax Biotechnology Co., Ltd., Chengdu 611731, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Xu","sequence":"additional","affiliation":[{"name":"Chengdu Olymvax Biotechnology Co., Ltd., Chengdu 611731, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Yang","sequence":"additional","affiliation":[{"name":"Chengdu Olymvax Biotechnology Co., Ltd., Chengdu 611731, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Xia","sequence":"additional","affiliation":[{"name":"Chengdu Olymvax Biotechnology Co., Ltd., Chengdu 611731, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ni","family":"Zeng","sequence":"additional","affiliation":[{"name":"Chengdu Olymvax Biotechnology Co., Ltd., Chengdu 611731, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaowen","family":"Fan","sequence":"additional","affiliation":[{"name":"Chengdu Olymvax Biotechnology Co., Ltd., Chengdu 611731, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanming","family":"Zou","sequence":"additional","affiliation":[{"name":"National Engineering Research Center of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy, Third Military Medical University, Chongqing 400038, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,3,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Oliveira, D., Borges, A., and Simoes, M. (2018). Staphylococcus aureus Toxins and Their Molecular Activity in Infectious Diseases. Toxins, 10.","DOI":"10.3390\/toxins10060252"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Lakhundi, S., and Zhang, K. (2018). Methicillin-Resistant Staphylococcus aureus: Molecular Characterization, Evolution, and Epidemiology. Clin. Microbiol. Rev., 31.","DOI":"10.1128\/CMR.00020-18"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1306801","article-title":"Multistate point-prevalence survey of health care-associated infections","volume":"370","author":"Magill","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: The WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.2147\/IDR.S175014","article-title":"Recent advances in Staphylococcus aureus infection: Focus on vaccine development","volume":"12","author":"Ansari","year":"2019","journal-title":"Infect. Drug Resist."},{"key":"ref_6","first-page":"491","article-title":"Vaccines for Staphylococcus aureus and Target Populations","volume":"409","author":"Pozzi","year":"2017","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_7","first-page":"208","article-title":"Staphylococcus aureus vaccine preclinical and clinical development: Current state of the art","volume":"41","author":"Redi","year":"2018","journal-title":"New Microbiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1001\/jama.2013.3010","article-title":"Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: A randomized trial","volume":"309","author":"Fowler","year":"2013","journal-title":"JAMA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.vaccine.2011.12.045","article-title":"The immunogenicity and safety of different formulations of a novel Staphylococcus aureus vaccine (V710): Results of two Phase I studies","volume":"30","author":"Harro","year":"2012","journal-title":"Vaccine"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"632","DOI":"10.4161\/hv.34414","article-title":"Efficacy profile of a bivalent Staphylococcus aureus glycoconjugated vaccine in adults on hemodialysis: Phase III randomized study","volume":"11","author":"Fattom","year":"2015","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1080\/21645515.2016.1248326","article-title":"Safety and immunogenicity of a recombinant Staphylococcus aureus alpha-toxoid and a recombinant Panton-Valentine leukocidin subunit, in healthy adults","volume":"13","author":"Landrum","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1016\/j.vaccine.2016.03.110","article-title":"Status of vaccine research and development of vaccines for Staphylococcus aureus","volume":"34","author":"Giersing","year":"2016","journal-title":"Vaccine"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.jinf.2016.08.004","article-title":"Safety and immunogenicity of a booster dose of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults: A randomized phase 1 study","volume":"73","author":"Marshall","year":"2016","journal-title":"J. Infect."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.vaccine.2016.11.010","article-title":"Safety, tolerability, and immunogenicity of a 4-antigen Staphylococcus aureus vaccine (SA4Ag): Results from a first-in-human randomised, placebo-controlled phase 1\/2 study","volume":"35","author":"Frenck","year":"2017","journal-title":"Vaccine"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"7594","DOI":"10.1016\/j.vaccine.2012.10.038","article-title":"NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults","volume":"30","author":"Schmidt","year":"2012","journal-title":"Vaccine"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1080\/21645515.2015.1011021","article-title":"Safety and immunogenicity of an investigational 4-component Staphylococcus aureus vaccine with or without AS03B adjuvant: Results of a randomized phase I trial","volume":"11","author":"Levy","year":"2015","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1128\/CVI.00399-16","article-title":"Safety and Immunogenicity of a Parenterally Administered, Structure-Based Rationally Modified Recombinant Staphylococcal Enterotoxin B Protein Vaccine, STEBVax","volume":"23","author":"Chen","year":"2016","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1093\/cid\/cis033","article-title":"Challenges for a universal Staphylococcus aureus vaccine","volume":"54","author":"Proctor","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/cid\/cir828","article-title":"Progress toward a Staphylococcus aureus vaccine","volume":"54","author":"Daum","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Zuo, Q.F., Yang, L.Y., Feng, Q., Lu, D.S., Dong, Y.D., Cai, C.Z., Wu, Y., Guo, Y., Gu, J., and Zeng, H. (2013). Evaluation of the protective immunity of a novel subunit fusion vaccine in a murine model of systemic MRSA infection. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0081212"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1007\/s11033-010-0317-6","article-title":"Fusion expression and immunogenicity of Bordetella pertussis PTS1-FHA protein: Implications for the vaccine development","volume":"38","author":"Jinyong","year":"2011","journal-title":"Mol. Biol. Rep."},{"key":"ref_22","first-page":"5","article-title":"The bicinchoninic acid (BCA) assay for protein quantitation","volume":"32","author":"Walker","year":"1994","journal-title":"Methods Mol. Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.3389\/fmicb.2018.01062","article-title":"PA0833 Is an OmpA C-Like Protein That Confers Protection Against Pseudomonas aeruginosa Infection","volume":"9","author":"Yang","year":"2018","journal-title":"Front. Microbiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1128\/IAI.74.4.2215-2223.2006","article-title":"A novel Staphylococcus aureus vaccine: Iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model","volume":"74","author":"Kuklin","year":"2006","journal-title":"Infect. Immun."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4889","DOI":"10.1128\/IAI.02328-14","article-title":"Vaccine protection of leukopenic mice against Staphylococcus aureus bloodstream infection","volume":"82","author":"Rauch","year":"2014","journal-title":"Infect. Immun."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1084\/jem.20072208","article-title":"Vaccine protection against Staphylococcus aureus pneumonia","volume":"205","author":"Schneewind","year":"2008","journal-title":"J. Exp. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1073\/pnas.1424924112","article-title":"Vaccine composition formulated with a novel TLR7-dependent adjuvant induces high and broad protection against Staphylococcus aureus","volume":"112","author":"Bagnoli","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Behrouz, B., Mahdavi, M., Amirmozafari, N., Fatemi, M.J., Irajian, G., Bahroudi, M., and Hashemi, F.B. (2016). Immunogenicity of Pseudomonas aeruginosa recombinant b-type fagellin as a vaccine candidate: Protective efficacy in a murine burn wound sepsis model. Burns.","DOI":"10.1016\/j.burns.2016.03.015"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"15553","DOI":"10.1038\/srep15553","article-title":"Protective Efficacy and Mechanism of Passive Immunization with Polyclonal Antibodies in a Sepsis Model of Staphylococcus aureus Infection","volume":"5","author":"Zhang","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1084\/jem.20092514","article-title":"Nontoxigenic protein A vaccine for methicillin-resistant Staphylococcus aureus infections in mice","volume":"207","author":"Kim","year":"2010","journal-title":"J. Exp. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1084\/jem.20020552","article-title":"Death by a B cell superantigen: In vivo VH-targeted apoptotic supraclonal B cell deletion by a Staphylococcal Toxin","volume":"197","author":"Goodyear","year":"2003","journal-title":"J. Exp. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.vaccine.2014.11.051","article-title":"Protein A-neutralizing monoclonal antibody protects neonatal mice against Staphylococcus aureus","volume":"33","author":"Thammavongsa","year":"2015","journal-title":"Vaccine"},{"key":"ref_33","first-page":"80","article-title":"Functionally inactive S. aureus alpha-toxin containing a single amino acid substitution: Potential usefulness as a vaccine","volume":"95","author":"Bhakdi","year":"1994","journal-title":"Behring Inst. Mitt."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1128\/iai.62.5.1843-1847.1994","article-title":"Site-directed mutagenesis of the alpha-toxin gene of Staphylococcus aureus: Role of histidines in toxin activity in vitro and in a murine model","volume":"62","author":"Menzies","year":"1994","journal-title":"Infect. Immun."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5443","DOI":"10.1021\/bi200369p","article-title":"Unique heme-iron coordination by the hemoglobin receptor IsdB of Staphylococcus aureus","volume":"50","author":"Gaudin","year":"2011","journal-title":"Biochemistry"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/infdis\/jiu198","article-title":"Humanized Staphylococcal Enterotoxin B (SEB)-Specific Monoclonal Antibodies Protect From SEB Intoxication and Staphylococcus aureus Infections Alone or as Adjunctive Therapy with Vancomycin","volume":"210","author":"Varshney","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1521-6616(03)00066-4","article-title":"Generation of protective immunity by inactivated recombinant staphylococcal enterotoxin B vaccine in nonhuman primates and identification of correlates of immunity","volume":"108","author":"Boles","year":"2003","journal-title":"Clin. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1128\/CVI.00078-10","article-title":"Oral vaccine formulations stimulate mucosal and systemic antibody responses against staphylococcal enterotoxin B in a piglet model","volume":"17","author":"Inskeep","year":"2010","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1128\/IAI.00420-13","article-title":"MntABC and MntH contribute to systemic Staphylococcus aureus infection by competing with calprotectin for nutrient manganese","volume":"81","author":"Zhang","year":"2013","journal-title":"Infect. Immun."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Salazar, N., Castiblanco-Valencia, M.M., da Silva, L.B., de Castro, \u00cd.A., Monaris, D., Masuda, H.P., Barbosa, A.S., and Ar\u00eaas, A.P.M. (2014). Staphylococcus aureus Manganese Transport Protein C (MntC) Is an Extracellular Matrix-and Plasminogen-Binding Protein. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0112730"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1093\/infdis\/jis272","article-title":"Staphylococcus aureus manganese transport protein C is a highly conserved cell surface protein that elicits protective immunity against S. aureus and Staphylococcus epidermidis","volume":"205","author":"Anderson","year":"2012","journal-title":"J. Infect. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.molmed.2018.12.010","article-title":"Considering the \u2019Alternatives\u2019 for Next-Generation Anti-Staphylococcus aureus Vaccine Development","volume":"25","author":"McLoughlin","year":"2019","journal-title":"Trends Mol. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1002\/bjs.10454","article-title":"Vaccine development to prevent Staphylococcus aureus surgical-site infections","volume":"104","author":"Mohamed","year":"2017","journal-title":"Br. J. Surg."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nrmicro3308","article-title":"Models matter: The search for an effective Staphylococcus aureus vaccine","volume":"12","author":"Schlievert","year":"2014","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.4049\/jimmunol.0900164","article-title":"Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity","volume":"183","author":"McKee","year":"2009","journal-title":"J. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1016\/j.vaccine.2019.04.055","article-title":"Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity","volume":"37","author":"Shi","year":"2019","journal-title":"Vaccine"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.4161\/hv.34407","article-title":"Mortality among recipients of the Merck V710 Staphylococcus aureus vaccine after postoperative S. aureus infections: An analysis of possible contributing host factors","volume":"10","author":"McNeely","year":"2014","journal-title":"Hum. Vaccines Immunother."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/8\/1\/134\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:07:51Z","timestamp":1760173671000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/8\/1\/134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,18]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,3]]}},"alternative-id":["vaccines8010134"],"URL":"https:\/\/doi.org\/10.3390\/vaccines8010134","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,18]]}}}